HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation products
- 1 January 2017
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 97, 22-29
Abstract
No abstract availableKeywords
Funding Information
- CAPES
- CNPq
This publication has 15 references indexed in Scilit:
- Analytical advances in pharmaceutical impurity profilingEuropean Journal of Pharmaceutical Sciences, 2016
- Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI–MSn, NMR and their synthesisJournal of Pharmaceutical and Biomedical Analysis, 2016
- Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug productTalanta, 2015
- Identification of the major degradation pathways of ticagrelorJournal of Pharmaceutical and Biomedical Analysis, 2015
- Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC MethodCurrent Pharmaceutical Analysis, 2014
- Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor TherapyJACC, 2011
- Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 2009
- Assuring quality of drugs by monitoring impurities☆Advanced Drug Delivery Reviews, 2007
- Validação em métodos cromatográficos e eletroforéticosQuímica Nova, 2004
- Central role of the P2Y12 receptor in platelet activationJournal of Clinical Investigation, 2004